BRIEF-Vincerx Reports Positive Initial Clinical Data From Ongoing Vip943 Phase 1 Dose-Escalation Study And Provides Pipeline And Corporate Updates

Reuters10-08

Vincerx Pharma Inc :

* VINCERX REPORTS POSITIVE INITIAL CLINICAL DATA FROM ONGOING VIP943 PHASE 1 DOSE-ESCALATION STUDY AND PROVIDES PIPELINE AND CORPORATE UPDATES

* VINCERX PHARMA INC - EXPECTED CASH RUNWAY INTO EARLY 2025

* VINCERX PHARMA INC - VINCERX FOCUSING RESOURCES ON CONTINUED DEVELOPMENT OF VIP943

* VINCERX PHARMA INC - VIP943 DEMONSTRATES PROMISING SAFETY AND TOLERABILITY AND ACHIEVES TWO COMPLETE RESPONSES TO DATE IN PHASE 1 DOSE-ESCALATION STUDY

* VINCERX PHARMA INC - ANTICIPATES PROVIDING ANOTHER DATA UPDATE ON ONGOING PHASE 1 VIP943 STUDY BY END OF YEAR.

Source text for Eikon: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2473435281?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-08 04:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2473435281","market":"us","top_or_hot":-1,"title":"BRIEF-Vincerx Reports Positive Initial Clinical Data From Ongoing Vip943 Phase 1 Dose-Escalation Study And Provides Pipeline And Corporate Updates","media":"Reuters","content":"<html><body><p>Vincerx Pharma Inc   :</p><p>   * VINCERX REPORTS POSITIVE INITIAL CLINICAL DATA FROM ONGOING VIP943 PHASE 1 DOSE-ESCALATION STUDY AND PROVIDES PIPELINE AND CORPORATE UPDATES</p><p>   * VINCERX PHARMA INC - EXPECTED CASH RUNWAY INTO EARLY 2025</p><p>   * VINCERX PHARMA INC - VINCERX FOCUSING RESOURCES ON CONTINUED DEVELOPMENT OF VIP943</p><p>   * VINCERX PHARMA INC - VIP943 DEMONSTRATES PROMISING SAFETY AND TOLERABILITY AND ACHIEVES TWO COMPLETE RESPONSES TO DATE IN PHASE 1 DOSE-ESCALATION STUDY</p><p>   * VINCERX PHARMA INC - ANTICIPATES PROVIDING ANOTHER DATA UPDATE ON ONGOING PHASE 1 VIP943 STUDY BY END OF YEAR.</p><p>Source text for Eikon:    Further company coverage:   </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Vincerx Reports Positive Initial Clinical Data From Ongoing Vip943 Phase 1 Dose-Escalation Study And Provides Pipeline And Corporate Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Vincerx Reports Positive Initial Clinical Data From Ongoing Vip943 Phase 1 Dose-Escalation Study And Provides Pipeline And Corporate Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-08 04:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vincerx Pharma Inc   :   * VINCERX REPORTS POSITIVE INITIAL CLINICAL DATA FROM ONGOING VIP943 PHASE 1 DOSE-ESCALATION STUDY AND PROVIDES PIPELINE AND CORPORATE UPDATES   * VINCERX PHARMA INC - ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VINC","symbol_name":"Vincera Pharma, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2473435281","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473435281","pubTimestamp":1728332853,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Vincerx Pharma Inc   :   * VINCERX REPORTS POSITIVE INITIAL CLINICAL DATA FROM ONGOING VIP943 PHASE 1 DOSE-ESCALATION STUDY AND PROVIDES PIPELINE AND CORPORATE UPDATES   * VINCERX PHARMA INC - EXPECTED CASH RUNWAY INTO EARLY 2025   * VINCERX PHARMA INC - VINCERX FOCUSING RESOURCES ON CONTINUED DEVELOPMENT OF VIP943   * VINCERX PHARMA INC - VIP943 DEMONSTRATES PROMISING SAFETY AND TOLERABILITY AND ACHIEVES TWO COMPLETE RESPONSES TO DATE IN PHASE 1 DOSE-ESCALATION STUDY   * VINCERX PHARMA INC - ANTICIPATES PROVIDING ANOTHER DATA UPDATE ON ONGOING PHASE 1 VIP943 STUDY BY END OF YEAR.Source text for Eikon:    Further company coverage:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VINC":"Vincera Pharma, Inc.","BK4139":"生物科技"},"translate_title":"简介-Vincerx报告了正在进行的VIP943 1期剂量递增研究的积极初始临床数据，并提供了管道和公司更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VINC":0.9},"content_text":"Vincerx Pharma Inc   :   * VINCERX REPORTS POSITIVE INITIAL CLINICAL DATA FROM ONGOING VIP943 PHASE 1 DOSE-ESCALATION STUDY AND PROVIDES PIPELINE AND CORPORATE UPDATES   * VINCERX PHARMA INC - EXPECTED CASH RUNWAY INTO EARLY 2025   * VINCERX PHARMA INC - VINCERX FOCUSING RESOURCES ON CONTINUED DEVELOPMENT OF VIP943   * VINCERX PHARMA INC - VIP943 DEMONSTRATES PROMISING SAFETY AND TOLERABILITY AND ACHIEVES TWO COMPLETE RESPONSES TO DATE IN PHASE 1 DOSE-ESCALATION STUDY   * VINCERX PHARMA INC - ANTICIPATES PROVIDING ANOTHER DATA UPDATE ON ONGOING PHASE 1 VIP943 STUDY BY END OF YEAR.Source text for Eikon:    Further company coverage:","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2473435281"}